

**Identity:**

Title: Professor  
 Family Name(s): Van Veldhuisen  
 First Name(s): Dirk J  
 Age: 64

**Photo:****Application for the following position in the HFA Board or Nominating Committee:**

Choose an item. Nominating Committee

**Place of work**

*If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.*

Institute/organisation:	University Medical Centre Groningen (UMCG)
Department:	Cardiology
Address:	Hanzeplein 1
Post code / Zip:	9713 EZ Groningen
Country:	the Netherlands

**General Curriculum Vitae (500 words max)**

*Please also include your H index and top 5 to 10 publications in the last 5 years*

Dirk J. van Veldhuisen, MD PhD FESC FACC (May 26th, 1959, The Netherlands)

Professor and Chairman of Cardiology at the University Medical Center Groningen, Groningen in the Netherlands since 2001.

Residency in Internal Medicine and Cardiology in Rotterdam and Groningen, the Netherlands.

Fellowships (> 3months) done in Switzerland, Groote Schuur Cape Town (South Africa) and Houston, TX (USA). Certified cardiologist since 1991; received his PhD in 1993 (Ibopamine in Heart Failure).

Established Investigator of the Netherlands Heart Foundation since 1997.

He has a long-standing interest in Clinical and Experimental Heart Failure.

Particular interests are the treatment of heart failure, including both pharmacologic and non-pharmacologic (device) interventions, neurohormonal activation, genetics, arrhythmias, and comorbidities, such as renal dysfunction/anemia.

H-index 146. He is the (co-) author of >1100 publications and had >80 PhD fellows in last 25 years.

Member of the editorial board of a number of journals and National Coordinator/Member of Steering Committees of >30 Heart Failure Trials, and Principal Investigator of 9 of them.

Principal Investigator of DECISION trial (Digoxin Evaluation in Chronic heart failure: Investigational Study in Outpatients in the Netherlands), a ongoing outcome study (started 2020, enrollment completed december 2023 (1002 patients); results expected in 2025. (Investigator-initiated study supported by the Netherlands Heart Foundation).

Chairman (1997-2002) and Member Working Group of Heart Failure, Netherlands Society of Cardiology. Recipient of large number of Grants from the Netherlands Heart Foundation.

Member of Heart Failure Association Board of the ESC (2008-2016).  
Member of the Task Force on the Guidelines Diagnosis and Treatment of Heart Failure 2008  
Member of the ESC Guidelines Heart Failure Update 2010.  
Member Task Force ESC Guideline on Ventricular Arrhythmias/Sudden Cardiac Death 2015.  
Editor-in-Chief of the European Journal of Heart Failure 2009-2014.

The UMC Groningen currently ranks #9 in the World in Cardiovascular Field (source:US news)

Best/most important 5 publications 2019-2023

1. **Van Veldhuisen DJ**, Bauersachs J. Digitalis in heart failure: declining use and ongoing outcome trials. *Eur Heart J.* 2023;44:1976-1978
2. Ter Maaten JM, Beldhuis IE, Van der Meer P, Krikken JA, Postmus D, Coster JE, Nieuwland W, **Van Veldhuisen DJ**, Voors AA, Damman K. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. *Nat Med.* 2023;29:2625-2632.
3. Van Veldhuisen SL, Gorter TM, Van Woerden G, De Boer RA, Rienstra M, Hazebroek EJ, **Van Veldhuisen DJ**. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. *Eur Heart J.* 2022;43:1955-1969.
4. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, Gao Q, Hasenfuss G, ... Solomon SD, Sverdllov AL, Swarup V, **Van Veldhuisen DJ**, Winkler S, Leon MB, on behalf of the REDUCE-LAP-HF II Investigators. *Lancet.* 2022;399:1130-1140.
5. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, **Van Veldhuisen DJ**, Zannad F, Zile MR, ..... Lefkowitz MP, for the PARAGON Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. *New Engl J Med* 2019;381:1609-20

**Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society**  
*150 words maximum*

For many years I have been on the board of the HFA (2008-2016), and partly through the HFA I have participated in the ESC Guidelines in 2008 (and its update in 2010). Moreover, I have had the privilege to be Editor of the European Journal of Heart Failure from 2009-2014 (after Prof. Karl Swedberg, and before Prof. Marco Metra), and to have the Editorial Board of the EJHF in Groningen.

On a national level, I have been member and later Chairman (1997-2002) of the Working Group of Heart Failure, Netherlands Society of Cardiology. In addition, I have served as chairman of the Scientific Committee of the Netherlands Heart Foundation "Diagnosis and Therapy" for six years (2004-2010), and have also received many National Grants for HF research.

**Why are you motivated to join the HFA Board or Nominating Committee?**  
*150 words maximum*

The Heart Failure Association (HFA) and its Board play a central and crucial role in the organization and development of HF research in Europe, and through the HFA, people learn new skills, and meet inspiring persons. With a well-functioning board, as it has been for many years, good HF projects, congresses and

collaborations can be made, which all help to improve HF research and patient care. On a personal level, through the HFA board, (new) members can also learn a lot themselves, and this certainly has also applied to me.

It would therefore be a big honour for me to be a member of the Nomination Committee of HFA Board of the ESC, and to assist in trying to get the best candidates.

**How will you combine your HFA position with your daily clinical/research workload?**

*80 words maximum*

In our hospital (UMC Groningen) research is a key part of our work, and in our department of Cardiology, Heart Failure has been the central research theme for the last 25 years.

Being the Head of my department allows me to make choices about priorities in time, and will give me more than enough time for the work as Nomination Committee member.